Labiotech.eu’s Post

🧠Exciting news in Alzheimer's therapeutics!🧠 This enlightening article highlights the dawn of a new era in the field. From monoclonal antibodies to gene therapies, innovative approaches are being embraced to tackle the disease from multiple angles. As we enter a new era of precision medicine, it's crucial to acknowledge the diverse efforts and collaborations driving progress in Alzheimer's research. Let's continue to support and invest in these transformative initiatives for the benefit of patients worldwide. #Alzheimers #PrecisionMedicine #Therapeutics #Innovation #Healthcare #Research 🧬🔬

Novartis’ Study Expands Hope for Spinal Muscular Atrophy Patients: Zolgensma’s Efficacy in Older Children Novartis has released data showing that its gene therapy, Zolgensma, is effective and safe in treating children aged 1.5 to 9.1 years with spinal muscular atrophy (SMA) who weigh between 8.5 kg and 21 kg. The study, called SMART, demonstrated that older and heavier patients experienced significant clinical benefits from Zolgensma, with participants maintaining or improving their motor milestones. The therapy's safety and tolerability were also confirmed, with manageable side effects and no new safety concerns. This expands the potential reach of Zolgensma and offers hope to the SMA community for broader access to treatments. For more details please click the link! https://lnkd.in/gVS2er_D #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

📃Scientific paper: Seven Solutions for Neuroprotection in Parkinson's Disease Abstract: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder Society Continued on ES/IODE ➡️ https://etcse.fr/FkilT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Proud to see C-Path's collaboration with The Michael J. Fox Foundation for Parkinson's Research on advancing Parkinson’s disease therapeutics through the use of the α-synuclein seed amplification assay biomarker featured in NeurologyLive. In the article, Diane Stephenson, Executive Director of the Critical Path for Parkinson's Consortium, emphasizes the significance of this breakthrough: “The new biomarker findings that have emerged in the last two years are truly transforming how we're going to be doing drug development for the future of Parkinson's... We now have a molecular tool that shows us the underlying biology of the disease in living individuals, allowing us to identify the right people to treat with promising new therapies, even years before symptoms appear." This coverage highlights the incredible progress made in PD research, particularly how this biomarker will help accelerate clinical trials and bring us closer to new, effective treatments for those impacted by the disease. Read the full article here: https://lnkd.in/g9rWJBzi #CPath #Parkinsons #DrugDevelopment #NeurologyLive #Collaboration #ParkinsonsDisease #BiomarkerResearch #ClinicalTrials #Innovation

In the realm of amyotrophic lateral sclerosis (ALS), patients are witnessing a significant transformation in treatment options, marking a long-awaited revolution. NeuroSense Therapeutics, in collaboration with Biogen, has propelled innovative therapies like PrimeC, offering promising results in mid-stage trials and the potential for combination with other treatments. The partnerships with established biotech firms highlight a joint effort to expedite the journey to market while upholding stringent regulatory standards. As NeuroSense navigates the intricate regulatory pathways and anticipates forthcoming neurofilament data, their focus extends beyond ALS, with encouraging progress in Alzheimer's disease and ongoing engagement with regulatory authorities. Amid these advancements, the profound impact on individual patients ignites optimism and reinforces our collective commitment to alleviating the burden of neurodegenerative diseases. At Archo, we're excited by these breakthroughs, recognizing their capacity to bring hope and relief to countless patients and their families. They exemplify the potency of collaboration and innovation in our ongoing mission to alleviate the challenges associated with ALS and other neurological conditions. #NeuroSense #ALS #PatientAdvocacy #HeathcareInnovation #PatientOutcomes

Myriad Genetics reported positive outcomes from a study of their GeneSight Psychotropic test, used in psychiatric treatment. The study involved 21,000 patients and revealed a 39% decrease in psychiatric-related hospitalizations post-test, along with a 29% reduction in all-cause hospitalizations. GeneSight testing lowered the proportion of patients prescribed medications with gene-drug interactions from 26.1% to 15.9%. Myriad acquired the GeneSight test through Assurex Health in 2016. They're also collaborating with Memorial Sloan Kettering Cancer Center on minimal residual disease testing for breast cancer using their MRD platform. Myriad offers diverse diagnostic tests, including BRACAnalysis CDx and EndoPredict for cancer detection. Do you think in the era of AI there will be more personalized treatments available and quicker ? (Recent News) –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– #Genetics #GeneSightPsychotropictest #Psychotropictest #clinical #psychiatrictreatment #psychiatricresearch #pharmaceutical #hospitalizationreduce #pharmacogeneticist #AssurexHealth #cancerresearch #companies #CRO #Biotechnology #Clinicaltrials #cancerdetection ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

Enhancing Stroke Treatment: NICE Proposes Genetic Testing for Personalized Care The National Institute for Health and Care Excellence (NICE) is proposing genetic testing as a way to enhance post-stroke care and tailor treatment based on patients' genetic makeup. The focus is on the CYP2C19 gene, which affects the response to the drug clopidogrel commonly used for stroke treatment. By identifying the most effective treatment regimen for stroke survivors, this approach could reduce the risk of subsequent strokes. It represents a shift towards personalized medicine and highlights the importance of integrating genetic insights into clinical practice. The initiative opens up new research opportunities in stroke treatment and prevention. NICE is recommending CYP2C19 genotype testing for individuals who have recently experienced a stroke or TIA to determine if clopidogrel is the best option for them. The testing should be done in the immediate aftermath of a stroke, as the utility decreases over time. The recommendation is aimed at improving stroke treatment outcomes in the UK, where a significant portion of the population carries the CYP2C19 gene variants. The implementation of this testing strategy will require expanding laboratory capacity. The proposal is seen as a significant advancement that offers hope for stroke survivors and alleviates the fear of recurrence. For more details please click the link! https://lnkd.in/dxHn9tqp #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

🎓 Excited to announce the publication of my first peer-reviewed article! 🔬 Title: "Targeting polo-like kinase 1 to treat kidney diseases" 🧬 Dive into the fascinating world of molecular pharmacology and nephrology as we explore the potential of polo-like kinase 1 (Plk1) in revolutionizing kidney disease treatments. This review synthesizes current research and offers new perspectives on: - The role of PLK1 in kidney cell regulation - How PLK1 inhibition could mitigate kidney damage involving different kidney disorders like AKI, CKD and many more ... - Promising avenues for future therapeutic interventions 📊 Published in the latest volume of the International Journal - Cell Biochemistry and Function (Wiley Publishing, Impact Factor: 2.8) 🔗 Read the full article here: https://lnkd.in/d69-xMHG 😇 I extend my sincere gratitude to Neha Dagar ma'am for her invaluable contributions and support throughout this research. My profound gratitude to my esteemed guide, Prof. Anil Gaikwad sir, whose mentorship and expertise were instrumental in bringing this work to fruition. I'd love to hear your thoughts! Whether you're a fellow researcher, healthcare professional, or simply curious about cutting-edge medical science, let's connect and discuss how we can advance kidney disease treatment together. #KidneyResearch #MolecularPharmacology #Plk1 #PeerReviewedResearch

#Article: Over the past two years, Eisai US and Biogen’s #Leqembi and Eli Lilly and Company’s #Kisunla, both #antiamyloid #antibodies, made history as the first real options to slow #cognitivedecline associated with #Alzheimersdisease. For years, #amyloidplaques and #tautangles have been a primary target of #Alzheimersdiseaseresearch and #drugdevelopment, but while affecting these proteins may yield some benefit, the illness continues to progress. Today, multiple therapeutics are in #PhaseIIItrials with other targets, suggesting that within the next few years it may become possible to treat #Alzheimer’s via multiple pathways. There are currently 32 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 in 48 Phase III trials, according to a recent paper by neuroscientist Jeffrey Cummings , a professor at the University of Nevada. Six of those target amyloid-β and one targets tau, but the others aim to affect neuroprotection growth factors, #neurotransmitters, #neurogenesis, inflammation and #proteinopathies. Of those, 21 are meant to be disease-modifying. “Alzheimer’s disease is quite complex in its biology and diagnosis,” Rebecca Edelmayer, vice president of scientific engagement for the Alzheimer's Association®, told BioSpace. “We’re moving to a point where we have better understanding of the disease and what contributes to its symptomology, so those biological underpinnings become targets.” These approaches won’t necessarily replace Leqembi and Kisunla, but they could increase therapeutic options to better manage the disease. Read full article in BioSpace 👇🏼